Neurocrine (NB3) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NB3 Analyst Ratings

Strong Buy

23 Buy

3 Hold

0 Sell

Based on 26 analysts giving stock ratings to

Neurocrine

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NB3 Stock 12 Month Forecast

Average Price Target

€182.75

▲(15.01% Upside)

Based on 26 Wall Street analysts offering 12 month price targets for Neurocrine in the last 3 months. The average price target is €182.75 with a high forecast of €215.37 and a low forecast of €147.04. The average price target represents a 15.01% change from the last price of €158.90.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"109":"€109","216":"€216","135.75":"€135.8","162.5":"€162.5","189.25":"€189.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":215.37258486000002,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€215.37</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":182.7466655792,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€182.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":147.0415238,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€147.04</span>\n  </div></div>","useHTML":true}}],"tickPositions":[109,135.75,162.5,189.25,216],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,144.9,150.32096806615385,155.7419361323077,161.16290419846155,166.5838722646154,172.00484033076924,177.4258083969231,182.84677646307694,188.26774452923078,193.68871259538463,199.10968066153848,204.53064872769232,209.95161679384617,{"y":215.37258486000002,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,144.9,147.81128196763078,150.72256393526155,153.63384590289232,156.5451278705231,159.45640983815386,162.3676918057846,165.27897377341537,168.19025574104614,171.10153770867691,174.01281967630769,176.92410164393846,179.83538361156923,{"y":182.7466655792,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,144.9,145.0647326,145.2294652,145.3941978,145.5589304,145.723663,145.8883956,146.0531282,146.2178608,146.3825934,146.547326,146.7120586,146.87679119999999,{"y":147.0415238,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":111.3,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.15,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.75,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.15,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.9,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":146.05,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":144.9,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€215.37

Average Price Target€182.75

Lowest Price Target€147.04

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Anupam Rama

J.P. Morgan

€160.02→€187.69

Buy

18.12%

Upside

Reiterated

08/06/26

J.P. Morgan Reaffirms Their Buy Rating on Neurocrine (NBIX)

Laura Chico

Wedbush

€160.02→€167.8

Buy

5.60%

Upside

Reiterated

08/03/26

Neurocrine price target raised to $194 from $185 at WedbushNeurocrine price target raised to $194 from $185 at Wedbush

Danielle Brill

Truist Financial

€184.23

Buy

15.94%

Upside

Reiterated

08/03/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY), Neurocrine (NASDAQ: NBIX) and Genmab (NASDAQ: GMAB)

Yigal Nochomovitz

Citi

€212.78→€215.37

Buy

35.54%

Upside

Reiterated

08/03/26

Neurocrine price target raised to $249 from $246 at CitiNeurocrine price target raised to $249 from $246 at Citi

Sumant Kulkarni

Canaccord Genuity

€172.99→€181.64

Buy

14.31%

Upside

Reiterated

08/03/26

Neurocrine (NBIX) Receives a Buy from Canaccord Genuity

Ami Fadia

Needham

€172.99→€176.45

Buy

11.04%

Upside

Assigned

07/31/26

Neurocrine Biosciences: Strong Q2 Beat, Upgraded Outlook, and Price Target Raised to $204 Support Buy Rating

Myles Minter

William Blair

―

Buy

―

Reiterated

07/31/26

Neurocrine Biosciences: Strong Q2 Execution, Expanded Pipeline, and Multi-Billion-Dollar Peak Sales Potential Support Buy Rating

Yatin Suneja

Guggenheim

€172.99→€192.02

Buy

20.84%

Upside

Reiterated

07/31/26

Neurocrine price target raised to $222 from $200 at GuggenheimNeurocrine price target raised to $222 from $200 at Guggenheim

Andrew Fein

H.C. Wainwright

€185.96

Buy

17.03%

Upside

Reiterated

07/31/26

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), Omnicell (NASDAQ: OMCL) and Guardant Health (NASDAQ: GH)

Jay Olson

Oppenheimer

€198.94

Buy

25.20%

Upside

Reiterated

07/31/26

Oppenheimer Sticks to Their Buy Rating for Neurocrine (NBIX)

David Amsellem

Piper Sandler

€179.04→€181.64

Buy

14.31%

Upside

Reiterated

07/31/26

Analysts Conflicted on These Healthcare Names: Siemens Healthineers AG (Other OTC: SEMHF), Neurocrine (NASDAQ: NBIX) and Karyopharm Therapeutics (NASDAQ: KPTI)

Paul Matteis

Stifel Nicolaus

€162.61→€185.96

Buy

17.03%

Upside

Reiterated

07/31/26

Neurocrine price target raised to $215 from $188 at StifelNeurocrine price target raised to $215 from $188 at Stifel

Sean Laaman

Morgan Stanley

€166.94→€169.53

Hold

6.69%

Upside

Reiterated

07/31/26

Neurocrine (NBIX) Gets a Hold from Morgan Stanley

David Hoang

Deutsche Bank

€147.04→€164.34

Hold

3.42%

Upside

Assigned

07/31/26

Neurocrine price target raised to $190 from $170 at Deutsche BankNeurocrine price target raised to $190 from $170 at Deutsche Bank

Mohit Bansal

Wells Fargo

€172.99

Buy

8.87%

Upside

Assigned

07/31/26

Wells Fargo recommends buying Neurocrine on weakness after solid quarterWells Fargo recommends buying Neurocrine on weakness after solid quarter

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Anupam Rama

J.P. Morgan

€160.02→€187.69

Buy

18.12%

Upside

Reiterated

08/06/26

J.P. Morgan Reaffirms Their Buy Rating on Neurocrine (NBIX)

Laura Chico

Wedbush

€160.02→€167.8

Buy

5.60%

Upside

Reiterated

08/03/26

Neurocrine price target raised to $194 from $185 at WedbushNeurocrine price target raised to $194 from $185 at Wedbush

Danielle Brill

Truist Financial

€184.23

Buy

15.94%

Upside

Reiterated

08/03/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY), Neurocrine (NASDAQ: NBIX) and Genmab (NASDAQ: GMAB)

Yigal Nochomovitz

Citi

€212.78→€215.37

Buy

35.54%

Upside

Reiterated

08/03/26

Neurocrine price target raised to $249 from $246 at CitiNeurocrine price target raised to $249 from $246 at Citi

Sumant Kulkarni

Canaccord Genuity

€172.99→€181.64

Buy

14.31%

Upside

Reiterated

08/03/26

Neurocrine (NBIX) Receives a Buy from Canaccord Genuity

Ami Fadia

Needham

€172.99→€176.45

Buy

11.04%

Upside

Assigned

07/31/26

Neurocrine Biosciences: Strong Q2 Beat, Upgraded Outlook, and Price Target Raised to $204 Support Buy Rating

Myles Minter

William Blair

―

Buy

―

Reiterated

07/31/26

Neurocrine Biosciences: Strong Q2 Execution, Expanded Pipeline, and Multi-Billion-Dollar Peak Sales Potential Support Buy Rating

Yatin Suneja

Guggenheim

€172.99→€192.02

Buy

20.84%

Upside

Reiterated

07/31/26

Neurocrine price target raised to $222 from $200 at GuggenheimNeurocrine price target raised to $222 from $200 at Guggenheim

Andrew Fein

H.C. Wainwright

€185.96

Buy

17.03%

Upside

Reiterated

07/31/26

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), Omnicell (NASDAQ: OMCL) and Guardant Health (NASDAQ: GH)

Jay Olson

Oppenheimer

€198.94

Buy

25.20%

Upside

Reiterated

07/31/26

Oppenheimer Sticks to Their Buy Rating for Neurocrine (NBIX)

David Amsellem

Piper Sandler

€179.04→€181.64

Buy

14.31%

Upside

Reiterated

07/31/26

Analysts Conflicted on These Healthcare Names: Siemens Healthineers AG (Other OTC: SEMHF), Neurocrine (NASDAQ: NBIX) and Karyopharm Therapeutics (NASDAQ: KPTI)

Paul Matteis

Stifel Nicolaus

€162.61→€185.96

Buy

17.03%

Upside

Reiterated

07/31/26

Neurocrine price target raised to $215 from $188 at StifelNeurocrine price target raised to $215 from $188 at Stifel

Sean Laaman

Morgan Stanley

€166.94→€169.53

Hold

6.69%

Upside

Reiterated

07/31/26

Neurocrine (NBIX) Gets a Hold from Morgan Stanley

David Hoang

Deutsche Bank

€147.04→€164.34

Hold

3.42%

Upside

Assigned

07/31/26

Neurocrine price target raised to $190 from $170 at Deutsche BankNeurocrine price target raised to $190 from $170 at Deutsche Bank

Mohit Bansal

Wells Fargo

€172.99

Buy

8.87%

Upside

Assigned

07/31/26

Wells Fargo recommends buying Neurocrine on weakness after solid quarterWells Fargo recommends buying Neurocrine on weakness after solid quarter

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Neurocrine

3 Months

Jay OlsonOppenheimer

Success Rate

17/26 ratings generated profit

Average Return

+3.75%

Copying Jay Olson's trades and holding each position for 3 Months would result in 65.38% of your transactions generating a profit, with an average return of +3.75% per trade.

1 Year

Anupam RamaJ.P. Morgan

Success Rate

22/31 ratings generated profit

Average Return

+9.07%

Copying Anupam Rama's trades and holding each position for 1 Year would result in 70.97% of your transactions generating a profit, with an average return of +9.07% per trade.

2 Years

Akash TewariJefferies

Success Rate

21/23 ratings generated profit

Average Return

+19.92%

Copying Akash Tewari's trades and holding each position for 2 Years would result in 91.30% of your transactions generating a profit, with an average return of +19.92% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NB3 Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NB3 has received 35 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. NB3 average Analyst price target in the past 3 months is 182.75.

Each month's total comprises the sum of three months' worth of ratings.

NB3 Financial Forecast

NB3 Earnings Forecast

Next quarter’s earnings estimate for NB3 is €1.67 with a range of €1.15 to €2.06. The previous quarter’s EPS was €1.21. NB3 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 55.56% of the time in the same period. In the last calendar year NB3 has Performed in-line its overall industry.

NB3 Sales Forecast

Next quarter’s sales forecast for NB3 is €900.94M with a range of €797.09M to €953.21M. The previous quarter’s sales results were €831.78M. NB3 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 43.48% of the time in the same period. In the last calendar year NB3 has Performed in-line its overall industry.

NB3 Stock Forecast FAQ

What is DE:NB3’s average 12-month price target, according to analysts?

Based on analyst ratings, Neurocrine’s 12-month average price target is 182.75.

What is DE:NB3’s upside potential, based on the analysts’ average price target?

Neurocrine has 15.01% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Neurocrine a Buy, Sell or Hold?

Neurocrine has a consensus rating of Strong Buy, which is based on 23 buy ratings, 3 hold ratings and 0 sell ratings.

What is Neurocrine’s share price target?

The average share price target for Neurocrine is 182.75. This is based on 26 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €215.37 ,and the lowest forecast is €147.04. The average share price target represents 15.01% Increase from the current price of €158.9.

What do analysts say about Neurocrine?

Neurocrine’s analyst rating consensus is a Strong Buy. This is based on the ratings of 26 Wall Streets Analysts.

How can I buy shares of Neurocrine?

To buy shares of DE:NB3, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Neurocrine (NB3) Stock Forecast & Price Target

NB3 Analyst Ratings

NB3 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Neurocrine

NB3 Analyst Recommendation Trends

NB3 Financial Forecast

NB3 Earnings Forecast

NB3 Sales Forecast

NB3 Stock Forecast FAQ

Detailed List of Analyst Forecasts